[HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
Hypersensitivity reactions to abacavir occur in 5-8% of patients starting treatment with this drug and limits future treatment. Some host genetic factors, especially the HLA-B*5701 allele, have been identified as risk factors for hypersensitivity reaction in Caucasians. Consequently, the possibility of routine implementation of a genetic test to rule out the presence of this allele has been proposed to achieve a personalized therapeutic profile. The present article discusses all the information related to hypersensitivity to abacavir and its genetic and immunological markers, as well as the distinct techniques for HLA-B*5701 allele detection. The various studies performed to date in distinct population are also discussed.
Arnedo Valero
Mireia
M
Servicio de Infecciosas, Hospital Clínic, IDIBAPS, Barcelona, España. marnedo@clinic.ub.es
D000483:Alleles; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000235:genetics* / Q000276:immunology; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D015658:HIV Infections / Q000188:drug therapy; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D005819:Genetic Markers; D015235:HLA-B Antigens; D000099227:Abacavir